Hrabal V, Stenckova M, Zavadil Kokas F, Muller P, Nenutil R, Vojtesek B
Sci Rep. 2024; 14(1):29949.
PMID: 39622910
PMC: 11612387.
DOI: 10.1038/s41598-024-80927-9.
Lopez I, Valdivia I, Vojtesek B, Fahraeus R, Coates P
Nucleic Acids Res. 2024; 52(20):12112-12129.
PMID: 39404067
PMC: 11551734.
DOI: 10.1093/nar/gkae855.
Liu L, Gong D, Sun H, Feng F, Xu J, Sun X
Front Immunol. 2024; 15:1470328.
PMID: 39380995
PMC: 11459316.
DOI: 10.3389/fimmu.2024.1470328.
Salustiano-Bandeira M, Moreira-Aguiar A, Pereira-Martins D, Coelho-Silva J, Weinhauser I, Franca-Neto P
Blood Cancer J. 2024; 14(1):102.
PMID: 38914584
PMC: 11196665.
DOI: 10.1038/s41408-024-01086-8.
Ando K, Nakagawara A
Cells. 2023; 12(4).
PMID: 36831211
PMC: 9954111.
DOI: 10.3390/cells12040544.
p53 Family in Resistance to Targeted Therapy of Melanoma.
Vlasic I, Horvat A, Tadijan A, Slade N
Int J Mol Sci. 2023; 24(1).
PMID: 36613518
PMC: 9820688.
DOI: 10.3390/ijms24010065.
Structural diversity of p63 and p73 isoforms.
Osterburg C, Dotsch V
Cell Death Differ. 2022; 29(5):921-937.
PMID: 35314772
PMC: 9091270.
DOI: 10.1038/s41418-022-00975-4.
p73 as a Tissue Architect.
Maeso-Alonso L, Lopez-Ferreras L, Marques M, Marin M
Front Cell Dev Biol. 2021; 9:716957.
PMID: 34368167
PMC: 8343074.
DOI: 10.3389/fcell.2021.716957.
Tissue-specific expression of p73 and p63 isoforms in human tissues.
Marshall C, Beeler J, Lehmann B, Gonzalez-Ericsson P, Sanchez V, Sanders M
Cell Death Dis. 2021; 12(8):745.
PMID: 34315849
PMC: 8316356.
DOI: 10.1038/s41419-021-04017-8.
p53/p73 Protein Network in Colorectal Cancer and Other Human Malignancies.
Horvat A, Tadijan A, Vlasic I, Slade N
Cancers (Basel). 2021; 13(12).
PMID: 34207603
PMC: 8227208.
DOI: 10.3390/cancers13122885.
Targeting Post-Translational Modifications of the p73 Protein: A Promising Therapeutic Strategy for Tumors.
Omran Z, Dalhat M, Abdullah O, Kaleem M, Hosawi S, Al-Abbasi F
Cancers (Basel). 2021; 13(8).
PMID: 33921128
PMC: 8071514.
DOI: 10.3390/cancers13081916.
TAp73β Can Promote Hepatocellular Carcinoma Dedifferentiation.
Iscan E, Ekin U, Yildiz G, Oz O, Keles U, Suner A
Cancers (Basel). 2021; 13(4).
PMID: 33668566
PMC: 7918882.
DOI: 10.3390/cancers13040783.
Role of Antizyme Inhibitor Proteins in Cancers and Beyond.
Tulluri V, Nemmara V
Onco Targets Ther. 2021; 14:667-682.
PMID: 33531815
PMC: 7846877.
DOI: 10.2147/OTT.S281157.
Splicing Genomics Events in Cervical Cancer: Insights for Phenotypic Stratification and Biomarker Potency.
Francies F, Bassa S, Chatziioannou A, Kaufmann A, Dlamini Z
Genes (Basel). 2021; 12(2).
PMID: 33498485
PMC: 7909518.
DOI: 10.3390/genes12020130.
Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway.
Bang S, Kaur S, Kurokawa M
Int J Mol Sci. 2020; 21(1).
PMID: 31905981
PMC: 6981958.
DOI: 10.3390/ijms21010261.
Epigenetic modification in the expression of p73 p73 - epigenetic target for anticancer therapy.
Naseer F, Saleem M
Oncol Rev. 2019; 13(2):421.
PMID: 31410249
PMC: 6661529.
DOI: 10.4081/oncol.2019.421.
TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).
Bunch B, Krishnan N, Greenspan R, Ramakrishnan S, Attwood K, Yan L
Cell Cycle. 2019; 18(17):2055-2066.
PMID: 31318640
PMC: 6681839.
DOI: 10.1080/15384101.2019.1638693.
Expression and clinical significance of p73 in Wilms tumor in children.
Ding Y, Guo X, Liu X, Li J, Li N, Xu C
Oncol Lett. 2019; 17(6):5435-5440.
PMID: 31186762
PMC: 6507322.
DOI: 10.3892/ol.2019.10249.
SIRT2-mediated inactivation of p73 is required for glioblastoma tumorigenicity.
Funato K, Hayashi T, Echizen K, Negishi L, Shimizu N, Koyama-Nasu R
EMBO Rep. 2018; 19(11).
PMID: 30213795
PMC: 6216266.
DOI: 10.15252/embr.201745587.
A Study on Effect of Oxaliplatin in MicroRNA Expression in Human Colon Cancer.
Evert J, Pathak S, Sun X, Zhang H
J Cancer. 2018; 9(11):2046-2053.
PMID: 29896290
PMC: 5995942.
DOI: 10.7150/jca.24474.